Diagnosis of breast cancer by analysis of sialic acid concentrations in human saliva by surface-enhanced Raman spectroscopy of silver nanoparticles
Diagnosis of breast cancer by analysis of sialic acid concentrations in human saliva by surface-enhanced Raman spectroscopy of silver nanoparticles
复制标题
DOI：
10.1007/s12274-017-1576-5
复制
发表时间：
2017-11-01
期刊：
影响因子：
9.9
通讯作者：
Ricardo Navarro-Contreras, Hugo
中科院分区：
文献类型：
--
作者：
Hernandez-Arteaga, Aida;Zermeno Nava, Jose de Jesus;Ricardo Navarro-Contreras, Hugo
乳腺癌是妇女中最常见的恶性肿瘤，也是癌症相关死亡的第二大原因。最常见的筛查和诊断方法是乳房X线摄影。尽管如此，还是发现了两个主要问题。首先，在测试期间接受的辐射剂量阻止了该方法用于< 40岁的女性。第二，由于肿瘤与纤维组织缺乏对比，乳房X线检查可能失败。因此，需要有助于识别高风险病例的筛查方法。我们开发了一种生物标志物测试，可以帮助识别它们。唾液中唾液酸（SA）水平的增加与乳腺癌有关。在这项研究中，我们评估了拉曼光谱作为唾液中SA的定量方法的可行性，使用柠檬酸还原银纳米粒子（cit-Ag-NPs）作为表面增强拉曼光谱（Sers）基板。通过测量唾液中SA的强度并将其与SA标准品的校准曲线进行比较来实现SA的定量。100名乳腺癌患者唾液中的平均SA浓度（18.3 +/- 9.4 mg.dL（-1）;平均值+/- SD）显著高于106名健康对照者（3.5 +/- 1.0 mg.dL（-1））。假设SA浓度> 7 mg.dL（-1）是阳性检测结果的截止值，Sers检测显示检测乳腺癌患者的灵敏度为94%，特异性为98%。我们的研究结果证明了这种Sers技术作为一种简单、方便、高灵敏度的唾液SA定量分析方法的实用性。这种纳米技术测试的简单性可能有助于大幅降低乳腺癌患者的死亡率，为女性提供一种简单的非侵入性筛查测试，无论年龄或乳腺组织密度如何，都可以应用。
Breast cancer is the most common type of malignant tumor among women and their second leading cause of cancer-related deaths. The most common method for screening and diagnosis is mammography. Nonetheless, two main problems have been identified. First, the dose of radiation received during the test prevents the method from the use on women who are < 40 years old. Second, there can be mammogram failure owing to the lack of tumor contrast with the fibrous tissue. Therefore, there is a need for screening methods that will help to identify high-risk cases. We developed a biological marker test that can help to identify them.Increased levels of sialic acid (SA) in saliva are known to correlated with breast cancer. In this study, we evaluated the feasibility of Raman spectroscopy as a method for quantification of SA in saliva, using citrate-reduced silver nanoparticles (cit-Ag-NPs) as a surface-enhanced Raman spectroscopy (SERS) substrate. Quantification of SA was accomplished by measuring its intensity in saliva and comparing it with a calibration curve of SA standards. The mean SA concentration in saliva was found to be significantly higher among 100 breast cancer patients (18.3 +/- 9.4 mg.dL(-1); mean +/- SD) than among 106 healthy controls (3.5 +/- 1.0 mg.dL(-1)). The SERS test showed sensitivity of 94% and specificity 98% for detection of patients with breast cancer, assuming that SA concentration > 7 mg.dL(-1) is a cutoff for positive test results. Our findings prove the usefulness of this SERS technique as a simple, convenient, and highly sensitive method of quantitative analysis of SA in saliva. The simplicity of this nanotechnological test may help to substantially reduce the mortality among patients with breast cancer by providing women with a simple, noninvasive screening test that can be applied regardless of age or density of breast tissue.